沙利度胺联合TACE治疗中晚期肝癌临床观察

目的观察沙利度胺联合TACE治疗中晚期肝癌的临床疗效及其影响。方法39例被确诊为中晚期肝癌，随机双盲服用沙利度胺或纤维索片100mg口服，早晚各一次，两周后200mg口服，早晚各一次，每两周加量200mg，至患者不能耐受，并联合TACE治疗，观察患者临床疗效及临床不良反应。结果治疗组（服用沙利度胺）半年生存率为77．8％，一年生存率为33．3％，AFP降低指数为1．50±0．86，对照组（服用纤维素片）分别为61．9％，28．6％，1．43±1．93，与治疗组对应比较均差异无显著性（P〉0．05）。结论沙利度胺联合TACE治疗晚期肝癌较单用TACE提高半年、一年生存率不显著，有较多副作用出现。

Clinical research on advanced primary carcinoma of liver treated with transcatheter arterial chemoembolization combined Thalidomide

Aim To observe the clinical efficacy and effect of Thalidomide combined with transcatheter arterial chemoembolization in treatment of advanced primary carcinoma of liver. Methods Thirty-nine patients were randomly divided into treatment group and control group, the patients of treatment group cpalend Thalidomide 100mg bis in die, 200mg bis in die after two weeks, to add 200mg fortnightly interval, and combined with TACE. The patients of control group were treated with TACE alone. To observe curative effect and clinical adverse effect. Results The six-month survival rates of the treatment group was 77.8% and the control group＇ s was 61.9%, there was no significant difference between the two groups （ P 〉 0.05 ）. The one-year survival rates of the treatment group was 33.3% and the control group＇ s was 28.6%, there was no significant difference between the two groups （ P 〉 0.05 ）. The alphafetoprotein decreasing rate of the treatment group was 1.50 ± 0.86, The alphafetoprotein decreasing rate of the control group was 1.43 ± 1.03, there was no significant difference between the two groups （P 〉 0.05）. Conclusions Compared with TACE along, the combination of TACE and thalidomide isn＇ t conspicuous for improving the six-month survival rates and the one-year survival rate of PLA patients and more side effects are occurrence.